<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        24-887-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEUKERAN 2 MG. TAB.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CHLORAMBUCIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        297
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="EXCELLA GmbH &amp; Co. KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            EXCELLA GmbH & Co. KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASPEN PHARMA TRADING LIMITED (APTL)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01AA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>What Leukeran is and what it is used for </strong>:</p><p>Leukeran contains an active substance called chlorambucil which belongs to a group of medicines called cytotoxics (also called chemotherapy). This medicine is used to treat certain type of cancers affecting human blood and lymphatic system. Your doctor will be able to explain how Leukeran might help in your particular condition.</p><p>Leukeran is used in patients with:</p><p>- <strong>Hodgkin&#39;s disease and Non-Hodgkin&rsquo;s Lymphoma.</strong> Together, these form a group of diseases called lymphomas. They are cancers formed from cells of the lymphatic system.</p><p>- <strong>Chronic lymphocytic leukaemia.</strong> A type of blood cancer where the bone marrow produces a large number of abnormal white blood cells.</p><p>- <strong>Waldenstrom&#39;s macroglobulinaemia.</strong> A rare lymphoma associated with an uncontrolled increase of B-cells, a type of white blood cell, resulting in the release of an abnormal protein into the blood.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2. What you need to know before you take Leukeran</strong></p><p><strong>Do not take Leukeran if:</strong></p><p>You are allergic to chlorambucil or any of the other ingredients of this medicine (listed in section 6).</p><p>Leukeran should not be used for the treatment of non-malignant cancer.</p><p>If you are not sure, talk to your doctor before taking Leukeran.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or nurse before you take this medicine if:</p><p>- You have been recently vaccinated, or planning to be vaccinated with a live vaccine (see Other medicines and Leukeran) as Leukeran can make your body less able to fight infections.</p><p>- You are a potential candidate for bone marrow transplantation (autologous stem cell transplantation) as the long term use of Leukeran may reduce the amount of stem cells.</p><p>- You have had radiotherapy or chemotherapy, now or recently.</p><p>- You have a liver disease.</p><p>- You have a kidney disease (nephrotic syndrome), had high pulse dosing regimen or ever had a fit or convulsion. If you have ever had fits or convulsions, you might be more at risk of having fits or convulsions when taking Leukeran.</p><p>It is possible that the use of Leukeran, particularly long term use, may increase the risk of developing a secondary blood cancer called acute secondary haematological malignancy. In many cases, patients who develop this have also received another type of chemotherapy or some form of radiation therapy. Symptoms of a secondary blood cancer include tiredness, fever, infection and bruising. Tell your doctor as soon as possible if you have any of these symptoms (see section 4).</p><p><strong>&nbsp;Other medicines and Leukeran</strong></p><p>Please tell your doctor if you are taking or have recently taken any of the following:</p><p>- Vaccines which contain live organisms (such as oral polio vaccine, measles, mumps, rubella).</p><p>- Phenylbutazone (a medicine used to treat fever, pain, and inflammation in the body)</p><p>- you may require a lower dose of Leukeran.</p><p>- Fludarabine, Pentostatin or Cladribine, which are other chemotherapy medicines that may be used for the treatment of certain blood cancers.</p><p>Please tell your doctor if you are taking or have recently taken or may take any other medicines, including medicines obtained without a prescription. This includes herbal medicines also.</p><p><strong>Leukeran with food</strong></p><p>Leukeran should be taken on an empty stomach. See section 3.</p><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, it is important to tell your doctor this before you are given Leukeran.</p><p>You should not take Leukeran if you are planning to have a baby. This applies to both men and women. Treatment with Leukeran is not recommended during pregnancy because it can be very damaging to your unborn baby.</p><p>You should not breast-feed while taking Leukeran.</p><p><strong>Fertility</strong></p><p>Leukeran can affect ovaries or sperm, which may cause infertility (inability to have a baby). In women menstruation can stop (amenorrhoea) and in men, a complete lack of sperm can be observed (azoospermia). Use a reliable form of contraception to avoid pregnancy if either you or your partner is taking Leukeran. Ask your doctor for advice.</p><p><strong>Driving and using machines</strong></p><p>No information on the effects of Chlorambucil on the ability to drive and use machines is available.</p><p><strong>Leukeran tablets contain lactose </strong></p><p>Leukeran tablets contain lactose, a type of sugar. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before you take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3. How to take Leukeran</strong></p><p>Always take Leukeran exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>Your doctor will advise you of how much and how often you will need to take this medicine. Your dosage is calculated based on your body weight and your disease.</p><p>- Leukeran tablet is administered orally. Food is known to affect the absorption of Leukeran therefore it is advisable to take Leukeran on an empty stomach (one hour before a meal or 3 hours after a meal).</p><ul><li>&nbsp; &nbsp; &nbsp; Leukeran treatment must be initiated and monitored under the supervision of a physician experienced in the antineoplastic agents.</li><li>&nbsp; &nbsp; Leukeran is a cytotoxic drug. Need caution when handling Leukeran to minimize risk of exposure.</li><li>&nbsp; &nbsp;Tablets should be swallowed whole.</li><li>&nbsp;The tablets should not be broken, chewed or crushed.</li></ul><p>The dose of Leukeran depends on the type of your disease condition (see section 1).</p><p>- Your doctor may change the dose during treatment depending on your needs. The drug dose can sometimes be changed if you are an older person or have liver problems. Your kidney or liver functions may be monitored during treatment, if you are an elderly person.</p><p>- While on Leukeran therapy, your doctor may take regular blood tests to check the number of cells in your blood, and your drug dose may be adjusted as a result.</p><p><strong>Hodgkin&rsquo;s Disease</strong></p><p>- The usual dose is 0.2 mg per kilogram of your body weight each day for adults and children.</p><p><strong>Non-Hodgkin&rsquo;s Lymphoma</strong></p><p>- The usual dose is 0.1 to 0.2 mg per kilogram of your body weight each day for adults and children.</p><p><strong>Chronic Lymphocytic Leukaemia</strong></p><p>- The usual starting dose is 0.15 mg per kilogram of your body weight each day.</p><p><strong>Waldenstrom&rsquo;s macroglobulinaemia</strong></p><p>- The usual starting dose is 6 to 12 mg each day.</p><p>Some people have to take Leukeran long term.</p><p>Follow your doctor&rsquo;s instructions carefully.</p><p><strong>If you take more Leukeran than you should</strong></p><p>Tell your doctor immediately or go to a hospital straight away. Ensure to take the medicine pack with you, even if there are no tablets left.</p><p><strong>If you forget to take Leukeran</strong></p><p>Tell your doctor. <strong>Do not take a double dose to make up for a forgotten dose.</strong></p><p><strong>If you stop taking Leukeran</strong></p><p>Do not stop taking Leukeran without your doctor&rsquo;s advice.</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4. Possible side effects</strong></p><p>Like all medicines, Leukeran can cause side effects, although not everybody gets them.</p><p><strong>If you experience any of the following, talk to your specialist doctor or go to hospital straight away:</strong></p><p>- any signs of a high temperature or infection (sore throat, sore mouth or urinary problems).</p><p>Treatment with Leukeran can cause a lowering of the white blood cell count. White blood cells fight infection, and when there are too few white blood cells, infections can occur.</p><p>- any <strong>unexpected</strong> bruising or bleeding, as this could mean that too few blood cells of a particular type are being produced</p><p>- if you <strong>suddenly</strong> feel unwell (even with a normal temperature)</p><p>- if you start feeling extremely tired</p><p>- if you notice numbness or weakness of your muscles</p><p>- if you experience skin rashes, blisters on the skin, sore mouth or eyes and have a high temperature.</p><p>Talk to your doctor if you have any of the following side effects, which may also happen with this medicine:</p><p><strong>Very Common (affects more than 1 in 10 people)</strong></p><p>- a drop in the number of blood cells, or bone marrow suppression.</p><p><strong>Common (affects less than 1 in 10 people)</strong></p><p>- feeling sick (nausea), being sick (vomiting), diarrhoea or mouth ulcers (sores),</p><p>- secondary blood cancers (acute secondary haematologic malignancies) especially after long term treatment,</p><p>- fits (convulsions) in children with a kidney problem known as nephrotic syndrome,</p><p>- a drop on red blood cells or anaemia which may make you feel tired or weak or breathless.</p><p><strong>Uncommon (affects less than 1 in 100 people)</strong></p><p>- rash.</p><p><strong>Rare (affects less than 1 in 1,000 people)</strong></p><p>- yellowing of the whites of the eyes or skin (jaundice),</p><p>- allergy symptoms such as skin lumps, hives (urticaria) or swelling of the face, eyelids, lips or throat (oedema),</p><p>- skin rash has been reported to progress to serious conditions including Stevens-Johnson syndrome and toxic epidermal necrolysis. These two forms of the same serious skin disease cause rash, skin peeling, and sores on the mucous membranes,</p><p>- fever,</p><p>- fit or convulsion,</p><p>- liver damage/injury (hepatotoxicity).</p><p><strong>Very rare (affects less than 1 in 10,000 people)</strong></p><p>- abnormal and repetitive shaking movement of the body or twitching, without fits or convulsions, condition affecting nerves leading to impairment of sensation, movement and organ function (peripheral neuropathy),</p><p>- inflammation of the bladder called cystitis,</p><p>- irreversible bone marrow failure - your body may stop producing blood cells transiently,</p><p>- scarring and thickening in the lungs with shortness of breath,</p><p>- a type of pneumonia that can cause scarring on the lungs,</p><p>- lung disease.</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>- absence of menstruation (amenorrhoea),</p><p>- absence of sperms in the semen (azoospermia).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5. How to store Leukeran</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date, which is stated on the bottle label and the carton after &lsquo;Exp&rsquo;. This is printed as month; year and refers to the last date of the month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original container.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator (2 and 8&deg;C).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Leukeran is a cytotoxic, need caution when handling to minimize risk of exposure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The tablets should not be divided, broken or crushed.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transport and store medicine in the original container or blister.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For medication administration, use gloves and wash hands thoroughly before and after. If gloves are not worn, tip tablets and from their container/blister pack directly into a disposable medicine cup.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; People who are not taking Leukeran should not be exposed to it.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caution should be observed in handling broken or crushed tablets Avoid direct contact of the Leukeran with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnant should avoid exposure to crushed or broken coated tablets.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Family members use gloves when handling laundry or cleaning within or around toilets.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Close the lid before flushing the toilet and flush twice after each use by patient, for 48 hours after receiving chemotherapy. If available, use separate bathroom from family members.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conduct double washing of linens and wash them separately from other family laundry.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor tells you to stop taking the medication, or if it expired.&nbsp; Do not throw away via wastewater or household waste. Ask your pharmacist how to throw away medicine you no longer use, or return it to your pharmacist, who will destroy them according to disposal of dangerous substance guidelines.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These measures will help protect environment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Only keep the medicine if your doctor tells you to.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Leukeran contains</strong></p><p>The active substance is chlorambucil. Each Leukeran tablet contains 2 mg of chlorambucil.</p><p>The other ingredients are microcrystalline cellulose, anhydrous lactose, colloidal anhydrous silica, stearic acid, hypromellose, titanium dioxide (E171), synthetic yellow iron oxide (E172), synthetic red iron oxide (E172) and macrogol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Leukeran tablets are brown, film-coated, round, biconvex tablets engraved ‘GX EG3’ on one side and ‘L’ on the other. Your Leukeran tablets are in bottles of 25 and 50 tablets.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p><strong>Marketing Authorisation holder:</strong></p><p>Aspen Pharma Trading Limited</p><p>3016 Lake Drive,</p><p>Citywest Business Campus, Dublin 24,</p><p>Ireland</p><p><strong>Manufacturer:</strong></p><p>Excella GmbH &amp; Co.KG</p><p>N&uuml;rnberger Strasse 12,</p><p>90537 Feucht,</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in {February/2022}; Version number {5}.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>1. التعريف بأقراص ليوكيران، ودواعي استخدامه</strong><br />تحتوي أقراص ليوكيران على مادة فعالة تسمّى كلورامبيوسيل، والتي تنتمي إلى مجموعة من الأدوية تسمى الأدوية السامة للخلايا (وتسمى أيضًا بالعلاج الكيميائي). ويُستخدم هذا الدواء لعلاج نوع معين من السرطانات يؤثر في دم الإنسان والجهاز اللمفاوي.<br />وسوف يتمكن الطبيب من توضيح إلى أي مدى يمكن أن تساعد أقراص ليوكيران حالتك المرضية المحددة.</p><p>تُستخدم أقراص ليوكيران مع المرضى المصابين بما يلي:<br />- <strong>داء هودجكين وسرطان الغدد اللمفاوية الغير هودجكينية.</strong> وتشكل هذه الأمراض معًا مجموعة من الأمراض تُسمى بالأورام اللمفاوية. وهي سرطانات تكوّنت من خلايا الجهاز اللمفاوي.<br />- <strong>سرطان الدم اللمفاوي المزمن.</strong> نوع من سرطانات الدم حيث ينتج نخاع العظام عددًا كبيرًا من خلايا الدم البيضاء غير الطبيعية.<br />-<strong> مرض فالدنستروم بفرط الجلوبولين الضخم </strong>هي حالة نادرة من الورم اللمفاوي يصاحبها ارتفاعٌ غير منضبط للخلايا البائية، إحدى أنواع خلايا الدم البيضاء؛ مما يؤدي إلى إفراز البروتين غير الطبيعي في الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>2 .ما تحتاج إلى معرفته قبل تناول أقراص ليوكيران</strong></p><p dir="RTL">&nbsp;إذا كنت تعاني من حساسية تجاه كلورامبيوسيل أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6). ينبغي عدم استخدام أقراص ليوكيران لعلاج السرطانات الحميدة.</p><p dir="RTL">إذا لم تكن متأكدًا، فيُرجى إبلاغ الطبيب قبل تناول الأقراص.</p><p dir="RTL"><strong>&nbsp;تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث إلى الطبيب أو الممرضة قبل تناول هذا الدواء في الحالات التالية:</p><p dir="RTL">- إذا كنت تناولت تطعيمًا مؤخرًا، أو تعتزم التطعيم بلقاحٍ حي (ارجع إلى قسم &quot;الأدوية الأخرى وأقراص ليوكيران)؛ حيث إنه من الممكن أن تُضعف أقراص ليوكيران الجسم في محاربته لحالات العدوى.</p><p dir="RTL">- إذا كنت من المرشحين المحتملين لزراعة نخاع العظام (زراعة الخلايا الجذعية ذاتية المنشأ)؛ حيث قد يؤدي طول فترة استخدام أقراص ليوكيران إلى انخفاض كمية الخلايا الجذعية.</p><p dir="RTL">- إذا كنت قد تعرّضت للعلاج الإشعاعي أو العلاج الكيميائي، في الفترة الحالية أو مؤخرًا.</p><p dir="RTL">- إذا كنت مصابًا بمرضٍ بالكبد.</p><p dir="RTL">-إذا كنت مصابًا بمرضٍ بالكلى (المتلازمة المرضيّة الكلوية)، أو كنت قد خضعت لنظام جرعات النبض العالي، أو حتى كنت مصابًا بنوبة أو تشنّج. فإذا سبق لك أن تعرّضت لنوبات أو تشنّجات، فربما تكون أكثر عرضة لخطر الإصابة لنوبات أو تشنّجات عند تناول الأقراص.</p><p dir="RTL">من المحتمل أن يؤدي استخدام أقراص ليوكيران، لا سيما الاستخدام طويل المدى، إلى خطورة الإصابة بسرطان ثانوي في الدم تسمى بالأورام الخبيثة الدموية الثانوية الحادة. وفي كثير من الحالات، يخضع المرضى الذين يصابون بهذا المرض أيضًا إلى نوع آخر من العلاج الكيميائي أو أحد أشكال العلاج الإشعاعي. تتضمن أعراض سرطان الدم الثانوي التعب والحمى والعدوى والكدمات. تحدث إلى الطبيب في أقرب وقت ممكن إذا كنت مصابًا بأي من هذه الأعراض (ارجع إلى القسم 4).</p><p dir="RTL"><strong>الأدوية الأخرى وأقراص ليوكيران </strong></p><p dir="RTL">يُرجى التحدث إلى الطبيب إذا كنت تتناول ما يلي أو كنت قد تناولته مؤخرًا:</p><p dir="RTL">- اللقاحات التي تحتوي على مواد عضوية حية (مثل لقاح شلل الأطفال عن طريق الفم، الحصبة، التهاب الغدة النكفية، الحصبة الألمانية).</p><p dir="RTL">- فينيل بوتازون (دواء يُستخدم لعلاج الحمى والألم والالتهاب في الجسم) - وقد تحتاج إلى جرعة أقل من أقراص ليوكيران.</p><p dir="RTL">- فلودارابين أو بنتوستاتين أو كلادريبن، وهي أدوية أخرى للعلاج الكيميائي قد تُستخدم لعلاج بعض سرطانات الدم.</p><p dir="RTL">يُرجى التحدث إلى الطبيب إذا كنت تتناول أي أدوية أخرى أو سبق لك تناولها أو ربما تتناولها، بما في ذلك الأدوية التي وُصفت لك من دون وصفة طبية. وهذا يتضمن الأدوية العشبية أيضًا.</p><p dir="RTL"><strong>&nbsp;أقراص ليوكيران مع الطعام </strong></p><p dir="RTL">ينبغي تناول أقراص ليوكيران على معدة فارغة. ارجع للقسم 3.&nbsp;</p><p dir="RTL"><strong>&nbsp;الحمل والرضاعة الطبيعية والخصوبة </strong></p><p dir="RTL">في حالة الحمل أو الرضاعة الطبيعية، أو التفكير في الحمل أو التخطيط له، من الأهمية بمكان التحدث إلى الطبيب قبل تناول أقراص ليوكيران.</p><p dir="RTL">وينبغي عدم تناول الأقراص في حالة التخطيط للحمل. وينطبق هذا الأمر على الرجال والنساء على حدٍ سواء. لا يوصى بالعلاج بأقراص ليوكيران أثناء الحمل؛ لأنها قد تكون مؤذية للغاية على الجنين.&nbsp;</p><p dir="RTL">ولا تنبغي الرضاعة الطبيعية أثناء تناول الأقراص.&nbsp;</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">من الممكن أن تؤثر أقراص ليوكيران في البويضات أو الحيوانات المنوية، والذي قد يسبب عقمًا (عدم القدرة على الإنجاب). وقد يتوقف الحيض عند النساء (انقطاع الطمث)؛ أما في الرجال، فمن الممكن ملاحظة انعدام تام للحيوانات المنوية. و يُرجى استخدام إحدى الوسائل الموثوقة لمنع الحمل لتجنّب الإنجاب إذا كنت تتناولين أنتِ أو زوجك أقراص ليوكيران. ويُرجى استشارة الطبيب.</p><p dir="RTL"><strong>&nbsp;القيادة واستخدام الماكينات </strong></p><p dir="RTL">لا تتوفر أي معلومات بشأن تأثيرات أقراص ليوكيران في القدرة على القيادة واستخدام الماكينات.</p><p dir="RTL"><strong>&nbsp;احتواء أقراص ليوكيران على اللاكتوز. </strong></p><p dir="RTL">تحتوي أقراص ليوكيران على اللاكتوز، وهو أحد أنواع السكر. وإذا أبلغك الطبيب بعدم القدرة على تحمل بعض السكريات، فيُرجى الاتصال به قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>3. كيفية تناول أقراص ليوكيران</strong></p><p dir="RTL">داوم على تناول أقراص ليوكيران تحديدًا حسب تعليمات الطبيب.ويُرجى الرجوع إلى الطبيب في حالة عدم التأكد. سوف ينصح الطبيب بالقدر الذي ستتناوله من هذا الدواء وبعدد المرات. تُحسب الجرعة على حسب المرض ووزن الجسم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تناول أقراص ليوكيران عن طريق الفم؛ ومن المعروف تأثير الطعام في امتصاص أقراص ليوكيران؛ لذا يُنصح بتناول الأقراص على معدةٍ فارغة (قبل ساعة من الوجبة، أو بعد الوجبة بثلاث ساعات).</p><ul dir="rtl"><li>&nbsp; يجب بدء العلاج بلوكيران ومراقبته تحت إشراف طبيب خبير في إدارة العوامل المضادة للأورام.</li><li>&nbsp; لوكيران دواء سام للخلايا. ينبغي توخي الحذر عند التعامل مع لوكيران للحد من مخاطر التعرض.</li><li>&nbsp; &nbsp;يجب ابتلاع الأقراص كاملة.</li><li>&nbsp; يجب ألا تُكسر الأقراص، أو تمضغ أو تسحق.</li></ul><p dir="RTL">تعتمد جرعة أقراص ليوكيران على نوع الحالة المرضيّة (ارجع القسم 1).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يغيّر الطبيب الجرعة أثناء العلاج حسب احتياجاتك. من الممكن تغيير جرعة الدواء أحيانًا إذا كنت كبيرًا في السن أو تعاني من مشكلات بالكبد، وقد تخضع وظائف الكلى أو الكبد إلى المراقبة أثناء العلاج إذا كنت كبيرًا في السن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يطلب الطبيب، أثناء العلاج بأقراص ليوكيران، فحوصات منتظمة للدم لفحص عدد الخلايا في الدم، وقد تتعدّل الجرعة نتيجةً لذلك.</p><p dir="RTL"><strong>الجرعة مع داء هودجكين</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة 0.2 ملجم لكل كيلوجرام من وزن الجسم كل يوم للبالغين والأطفال.</p><p dir="RTL"><strong>الجرعة مع سرطان الغدد اللمفاوية الغير هودجكينية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتراوح الجرعة المعتادة ما بين 0.1 و 0.2 ملجم لكل كيلوجرام من وزن الجسم كل يوم للبالغين والأطفال.</p><p dir="RTL"><strong>سرطان الدم اللمفاوي المزمن.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة للبداية 0.15 ملجم لكل كيلوجرام من وزن الجسم كل يوم.</p><p dir="RTL"><strong>مرض فالدنستروم بفرط الجلوبولين الضخم</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتراوح الجرعة المعتادة للبداية ما بين 6 إلى 12 ملجم كل يوم.</p><p dir="RTL">ويجب على بعض المرضى تناول أقراص ليوكيران لفترة طويلة. لذا يُرجى اتباع تعليمات الطبيب بعناية.</p><p dir="RTL"><strong>الإفراط في تناول أقراص ليوكيران</strong></p><p dir="RTL">يُرجى التحدّث إلى الطبيب على الفور أو الذهاب إلى المستشفى في الحال. وتأكد من أخذ عبوة الدواء معك، حتى إذا لم يكن بها أي أقراص.</p><p dir="RTL"><strong>عند نسيان تناول أقراص ليوكيران</strong></p><p dir="RTL">تحدّث إلى الطبيب.<strong> وتجنّب تناول جرعة مزدوجة لتعويض جرعة فائتة.</strong></p><p dir="RTL"><strong>عند التوقف عن تناول أقراص ليوكيران</strong></p><p dir="RTL">تجنّب التوقف عن تناول أقراص ليوكيران من دون استشارة الطبيب.</p><p dir="RTL">وإذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، فيُرجى سؤال الطبيب أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>4. الآثار الجانبية المحتملة</strong></p><p dir="RTL">قد تسبب أقراص ليوكيران، مثل جميع الأدوية، آثارًا جانبية، على الرغم من عدم تعرّض الجميع لها.&nbsp;</p><p dir="RTL"><strong>إذا كنت تعاني من الأمراض التالية، فتحدث إلى طبيب متخصص أو اذهب إلى المستشفى في الحال:</strong></p><ul dir="rtl"><li>&nbsp; أي أعراض لارتفاع درجة الحرارة أو الإصابة بالعدوى(التهاب الحلق أو قرحة الفم أو مشكلات في المسالك البولية) فقد يؤدي العلاج بأقراص ليوكيران إلى انخفاض عدد كريات الدم البيضاء. فخلايا الدم البيضاء تحارب العدوى؛ وعند وجود عدد قليل منها، قد تظهر حالات العدوى بالجسم.</li><li>&nbsp;أي كدمات أو نزيف <strong>غير متوقع</strong> ، حيث قد يعني ذلك إنتاج كريات دم قليلة جدًا من نوع خاص.</li><li>إذا شعرت <strong>فجأة</strong> بوعكةٍ صحية (حتى مع دراجة الحرارة العادية)</li><li>&nbsp;إذا بدأت في الشعور بالإجهاد الشديد.</li><li>&nbsp;إذا لاحظت تنميلاً أو ضعفًا في العضلات.</li><li>&nbsp;إذا تعرّضت لطفح جلدي، أو بروز على الجلد، أو احتقان الفم أو العينين</li></ul><p dir="RTL">تحدث إلى الطبيب إذا كنت مصابًا بأي من الآثار الجانبية التالية، والتي قد تحدث أيضًا بسبب هذا الدواء:</p><p dir="RTL">آثار شائعة جدًا (تؤثر في أكثر من شخص من بين 10 أشخاص)</p><ul dir="rtl"><li>&nbsp;هبوط في عدد كريات الدم، أو تثبيط نخاع العظام.</li></ul><p dir="RTL"><strong>آثار شائعة (</strong><strong>تؤثر في أقل من شخص من بين 10 أشخاص</strong><strong>)</strong></p><ul dir="rtl"><li>&nbsp; الشعور بالمرض (غثيان)، الشعور بالإعياء (قيء)، الإسهال أو قرحات الفم (حالات احتقان)،</li><li>سرطانات ثانوية في الدم (الأورام الخبيثة الدموية الثانوية الحادة)، لا سيما بعد فترة طويلة من العلاج.</li><li>&nbsp;نوبات (تشنجات) مع الأطفال المصابة بمشكلة في الكلى تُعرف باسم المتلازمة المرضيّة الكلوية.</li><li>هبوط في كريات الدم الحمراء أو فقر الدم الذي قد يؤدي إلى الشعور بالإجهاد أو الضعف أو ضيق التنفس.</li></ul><p dir="RTL"><strong>آثار غير شائعة (تؤثر في أقل من شخص من بين 100 شخص)</strong></p><ul dir="rtl"><li>طفح جلدي.</li></ul><p dir="RTL"><strong>آثار نادرة (</strong><strong>تؤثر في أقل من شخص من بين 1000 شخص</strong><strong>)</strong></p><ul dir="rtl"><li>&nbsp; اصفرار أو ابيضاض العينين أو الجلد (الصفراء)،</li><li>&nbsp;أعراض الحساسية مثل انتفاخات في الجلد، حساسية الجلد(أرتيكاريا) أو تورم الوجه أو الجفنين أو الشفتين أو الحلق&nbsp;&nbsp;(وذمة)،</li><li>تم البلاغ عن حدوث حالات تطور فيها الطفح الجلدي الى حالات مرضيه خطيره ، بما في ذلك متلازمة ستيفينز- جونسون وإنحلال البشرة السمٌي. تسبب هاتان الصورتان من نفس المرض الجلدي الخطير طفحًا جلديًا وتقشر الجلد، واحتقانات في الأغشية المخاطية،</li><li>الحمى،</li><li>نوبة أو تشنّج،</li><li>&nbsp;تلف/إصابة الكبد (تسمم الكبد)</li></ul><p dir="RTL"><strong>آثار نادرة جدًا </strong><strong>(</strong><strong>تؤثر في أقل من شخص من بين 10000 شخص</strong><strong>)</strong></p><ul dir="rtl"><li>حركات اهتزاز أو رعشة غير طبيعية ومتكررة للجسم، من دون نوبات أو تشنّجات، وهي حالة مرضيّة تؤثر في الأعصاب، مما يؤدي إلى ضعف الإحساس والحركة ووظائف الأعضاء (اعتلال الأعصاب الطرفية)،</li><li>التهاب في المثانة،</li><li>فشل نخاع العظام غير قابل للشفاء فقد يتوقف الجسم عن إنتاج كريات الدم مؤقتًا،</li><li>ظهور ندبات في الرئتين وسماكتها، يصاحبه ضيق في التنفس،</li><li>نوع من الالتهاب الرئوي قد يسبب تندب الرئتين،</li><li>مرض الرئتين.</li></ul><p dir="RTL"><strong>آثار غير معروفة </strong><strong>(</strong><strong>لا يمكن تقدير معدل تكرار الحدوث من البيانات المتاحة</strong><strong>)</strong></p><ul dir="rtl"><li>غياب الحيض (انقطاع الطمث)</li><li>غياب الحيوانات المنوية في السائل المنوي (انعدام الحيوانات المنوية)</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>5. كيفية تخزين أقراص ليوكيران</strong></p><ul dir="rtl"><li>&nbsp; &nbsp;يُحفظ هذا الدواء بعيدًا عن أعين الأطفال ومتناول أيديهم.</li><li>&nbsp; &nbsp; &nbsp; تجنّب استخدام هذا الدواء بعد تاريخ انتهاء الصلاحية، والمبيّن على ملصق الزجاجة والعبوة الكرتونية بعد كلمة &quot;. Exp&quot; والتاريخ مطبوع في صيغة شهر؛ سنة، ويُشير إلى التاريخ الأخير من الشهر.</li><li>&nbsp; &nbsp;يُرجى الحفظ في العبوة الأصلية.</li><li>&nbsp; &nbsp;ويُحفظ في الثلاجة (ما بين 2 إلى 8 درجات مئوية).</li><li>&nbsp; &nbsp; &nbsp;لوكيران دواء سام للخلايا. ينبغي توخي الحذر عند التعامل معه للحد من مخاطر التعرض.</li><li>&nbsp;يجب ألا تُكسر الأقراص، أو تمضغ أو تسحق.</li><li>&nbsp; &nbsp; &nbsp;يُنقل الدواء ويُخزن في الشريط أو الحاوية الأصلية.</li><li>&nbsp; &nbsp;لتقديم الدواء، تُستخدم القفازات وتُغسل اليدين جيداً قبل تقديم الدواء وبعده. في حالة عدم ارتداء القفازات، تقلب الأقراص من عبوتها/ الشريط مباشرة في كوب طبي يمكن التخلص منه.</li><li>&nbsp; &nbsp;الأشخاص الذين لا يتناولون لوكيران يجب ألا يتعرضوا له.</li><li>&nbsp; يجب توخي الحذر عند التعامل مع أقراص مكسورة أو مسحوقة. تجنب التلامس المباشر للوكيران مع الجلد أو الأغشية المخاطية. في حالة حدوث التلامس، يُغسل موضع التلامس جيداً بالماء والصابون، وتُشطف العينين جيداً بماء معقم، أو ماء عادي في حالة عدم توفر الماء المعقم.</li><li>&nbsp;ينبغي على السيدات الحوامل تجنب التعرض للأقراص المسحوقة أو المكسورة.</li><li>&nbsp; يجب على أفراد الأسرة استخدام القفازات عند التعامل مع الغسيل أو التنظيف داخل المراحيض أو حولها.</li><li>&nbsp; أغلق الغطاء قبل شطف المرحاض بالدفق واشطفه مرتين بعد كل استخدام من قبل المريض، وذلك لمدة 48 ساعة بعد تلقي العلاج الكيميائي. عند التوفر، استخدم حماماً منفصلاً عن الحمام الذي يستخدمه أفراد الأسرة.</li><li>&nbsp; &nbsp;يجب غسل البياضات غسلاً مزدوجاً وتغسل بشكل منفصل عن غسيل الأسرة الآخر.</li><li>&nbsp; &nbsp;إذا أخبرك الطبيب بالتوقف عن تناول الدواء، أو انتهت صلاحيته. ssلا تتخلص من الدواء في ماء الصرف الصحي أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها، أو أعدها إلى الصيدلي الذي سيقوم بإتلافها وفقاً لإرشادات التخلص من المواد الخطرة.</li><li>&nbsp; &nbsp; &nbsp;ستساعد هذه الإجراءات في الحفاظ على البيئة.</li><li>&nbsp; &nbsp; &nbsp;احتفظ بالدواء فقط إذا أخبرك طبيبك بذلك.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي ليوكيران</strong></p><p dir="RTL">المادة الفعالة في الأقراص هي كلورامبيوسيل. ويحتوي كل قرص من ليوكيران على 2 ملجم من كلورامبيوسيل.</p><p dir="RTL">أما عن المكونات الأخرى، فهي سيليلوز بلوري مكروى، لاكتوز لا مائي، سيليكا لا مائية غروانية، حمض دهني، هيبروميلوز، ثاني أكسيد التيتانيوم (E171)، ثاني أكسيد الحديد الأصفر المصنع (E172)، ثاني أكسيد الحديد الأحمر المصنع (E172)، ماكروجول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل أقراص ليوكيران ومحتويات العبوة</strong></p><p dir="RTL">أقراص ليوكيران بنيّة اللون ومغلفة ودائرية ومحدبة الوجهين، محفور عليها &quot; GX EG3&quot; &nbsp;على أحد الجانبين، وحرف L على الجانب الآخر. تأتي أقراص ليوكيران في زجاجات من 25 قرصا و 50 قرصا.</p><p dir="RTL">قد لا تتوفر جميع أحجام العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التفويض بالتسويق والجهة المصنّعة</strong></p><p dir="RTL"><strong>مالك حق التفويض بالتسويق:</strong></p><p dir="RTL">أسبن فارما تريدينج المحدودة، 3016 ليك درايف</p><p dir="RTL">&nbsp;سيتي ويست بزنس كامبوس، دبلن 24</p><p dir="RTL">أيرلندا</p><p dir="RTL"><strong>الجهة المصنّعة:</strong></p><p dir="RTL">إكسيلا و شركاؤه المحدودة</p><p dir="RTL">طريق نورنرجر 12،</p><p dir="RTL">90537 فويشت،</p><p dir="RTL">ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في{فبراير/2022}، رقم النسخة {5}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Leukeran 2 mg Film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 2 mg of the active ingredient chlorambucil. 
Excipient(s) with known effect:
Each tablet also contains 67.65 mg of lactose.
 For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (Tablet)
Brown, round, biconvex tablet, engraved on one side with “L” and “GX EG3” on the other.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Leukeran is indicated in the treatment of:<br />- Hodgkin&#39;s disease;<br />- Certain forms of non-Hodgkin&#39;s lymphoma;<br />- Chronic lymphocytic leukaemia;<br />- Waldenstrom&#39;s macroglobulinaemia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General: </u></p><p>Leukeran treatment must be initiated and monitored under the supervision of a physician experienced in oncology service.</p><p>THE RELEVANT LITERATURE SHOULD BE CONSULTED FOR FULL DETAILS OF THE TREATMENT SCHEDULES USED.</p><p>LEUKERAN IS AN ACTIVE CYTOTOXIC AGENT AND SHOULD ONLY BE ADMINISTERED UNDER THE DIRECTION OF A SPECIALIST ONCOLOGY SERVICE HAVING THE FACILITIES FOR REGULAR MONITORING OF CLINICAL BIOCHEMICAL AND HAEMATOLOGICAL EFFECTS DURING AND AFTER ADMINISTRATION.</p><p><u>Posology</u></p><p><em>Hodgkin&#39;s disease</em></p><p>Used as a single agent in the palliative treatment of advanced disease, a typical dosage is 0.2 mg/kg/day for 4-8 weeks.</p><p>Leukeran is usually included in combination therapy and a number of regimes have been used. Leukeran has been used as an alternative to nitrogen mustard with a reduction in toxicity but similar therapeutic results.</p><p><em>Non-Hodgkin&#39;s lymphoma</em></p><p>Used as a single agent the usual dosage is 0.1-0.2 mg/kg/day for 4-8 weeks initially; maintenance therapy is then given either by a reduced daily dosage or intermittent courses of treatment.</p><p>Leukeran is useful in the management of patients with advanced diffuse lymphocytic lymphoma and those who have relapsed after radiotherapy.</p><p>There is no significant difference in the overall response rate obtained with chlorambucil as a single agent and combination chemotherapy in patients with advanced non-Hodgkin&#39;s lymphocytic lymphoma.</p><p><em>Chronic lymphocytic leukaemia</em></p><p>Treatment with Leukeran is usually started after the patient has developed symptoms or when there is evidence of impaired bone marrow function (but not marrow failure) as indicated by the peripheral blood count.</p><p>Initially Leukeran is given at a dosage of 0.15 mg/kg/day until the total leukocyte count has fallen to 10,000 per ml.</p><p>Treatment may be resumed 4 weeks after the end of the first course and continued at a dosage of 0.1 mg/kg/day.</p><p>In a proportion of patients usually after about 2 years of treatment, the blood leukocyte count is reduced to the normal range, enlarged spleen and lymph nodes become impalpable and the proportion of lymphocytes in the bone marrow is reduced to less than 20 per cent.</p><p>Patients with evidence of bone marrow failure should first be treated with prednisolone and evidence of marrow regeneration should be obtained before commencing treatment with Leukeran.</p><p>Intermittent high dose therapy has been compared with daily Leukeran but no significant difference in therapeutic response or frequency of side effects was observed between the two treatment groups.</p><p><em>Waldenstrom&#39;s macroglobulinaemia</em></p><p>Leukeran is one of the treatment choices in this indication.</p><p>Starting doses of 6-12 mg daily until leukopenia occurs are recommended followed by 2-8 mg daily indefinitely.</p><p><em>SPECIAL POPULATIONS</em></p><p><em>Renal impairment</em></p><p>Chlorambucil has an extremely low urinary excretion and hence renal excretion is not considered an important pathway in chlorambucil elimination. Dose adjustment is not considered necessary in renally impaired patients. However no formal studies of the effects of renal insufficiency on the pharmacokinetics of chlorambucil have been carried out.</p><p><em>Hepatic impairment</em></p><p>Patients with hepatic impairment should be closely monitored for signs and symptoms of toxicity. Since chlorambucil is primarily metabolized in the liver, dose reduction should be considered in patients with severe hepatic impairment. However, there are insufficient data in patients with hepatic impairment to provide a specific dosing recommendation.</p><p><em>Paediatric population</em></p><p>Leukeran may be used in the management of Hodgkin&#39;s disease and non-Hodgkin&#39;s lymphomas in the paediatric population. The dosage regimens are similar to those used in adults.</p><p>Use in the elderly</p><p>No specific studies have been carried out in the elderly, however, it may be advisable to monitor renal or hepatic function and if there is impairment then caution should be exercised.</p><p>While clinical experience has not revealed age-related differences in response, drug dosage generally should be titrated carefully in elderly patients, usually initiating therapy at the low end of the dosage range.</p><p><u>Method of administration</u></p><p>Leukeran is taken orally. High gastric pH has been shown to significantly decrease the bioavailability of Leukeran therefore ingestion on an empty stomach (one hour before a meal or 3 hours after) is advised.</p><ul><li>&nbsp;Leukeran is a cytotoxic drug. Follow applicable special handling and disposal procedures (see section 6.6).</li><li>Tablets should be swallowed whole.</li><li>The tablets should not be broken or crushed, if possible. This might produce powder that can contaminate workplace surfaces.</li><li>&nbsp;If tablet must be cut or crushed, this should be done by a professional trained personal experienced in safe handling of cytotoxic drugs using an appropriate equipment and safety procedures. &nbsp;</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Use in the management of patients with non-malignant disease.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immunisation using a live organism vaccine has the potential to cause infection in immunocompromised individuals. Therefore, immunisations with live organism vaccines are not recommended.</p><p>Patients who will potentially have autologous stem cell transplantation should not be treated with chlorambucil long term.</p><p>Safe handling of Leukeran Tablets</p><p>See section 6.6.</p><p><u>Monitoring</u><br />Since Leukeran is capable of producing irreversible bone marrow suppression, blood counts should be closely monitored in patients under treatment. Total dosage in the region of 6.5 mg/kg bodyweight is associated with the risk of irreversible bone marrow damage.</p><p>At therapeutic dosage Leukeran depresses lymphocytes and has less although progressive effect on neutrophil and platelet counts and on haemoglobin levels. Discontinuation of Leukeran is not necessary at the first sign of a fall in neutrophils but it must be remembered that the fall may continue for 10 days or more after the last dose.</p><p>Leukeran should not be given to patients who have recently undergone radiotherapy or received other cytotoxic agents. Leukeran should only be used with caution in patients with depressed bone narrow function or lymphocytic infiltration of same. When lymphocytic infiltration of the bone marrow is present or the bone marrow is hypoplastic, the daily dose should not exceed 0.1 mg/kg bodyweight.</p><p>The paediatric population with nephrotic syndrome, patients prescribed as high pulse dosing regimens and patients with a history of seizure disorder, should be closely monitored following administration of Leukeran, as they may have an increased risk of seizures.</p><p><u>Mutagenicity and carcinogenicity</u><br />Chlorambucil has been shown to cause chromatid or chromosome damage in man and has been shown to be carcinogenic in animals. The possibility of a similar effect should be borne in mind when designing the long-term management of the patient. Acute secondary haematologic malignancies (especially leukaemia and myelodysplastic syndrome) have been reported, particularly after long term treatment (see section 4.8). A comparison of patients with ovarian cancer, who received alkylating agents with those who did not, showed that the use of alkylating agents, including chlorambucil, significantly increased the incidence of acute leukaemia. Acute myelogenous leukaemia has been reported in a small proportion of patients receiving chlorambucil as long term adjuvant therapy for breast cancer.</p><p>The leukaemogenic risk must be balanced against the potential therapeutic benefit when considering the use of chlorambucil.</p><p><u>Sugar intolerances</u><br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vaccinations with live organism vaccines are not recommended in immunocompromised individuals (see section 4.4).</p><p>Purine nucleoside analogues (such as fludarabine, pentostatin and cladribine) increased the cytotoxicity of chlorambucil ex vivo. Clinically the combination of purine nucleoside analogues and alkylating agents have been shown to produce high disease response rates however the combinations have also resulted in higher rates of haematological toxicities. Animal studies indicate that patients who receive phenylbutazone may require a reduction of the standard chlorambucil doses because of the possibility of enhanced chlorambucil toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />As with all cytotoxic chemotherapy, adequate contraceptive precautions should be advised when either partner is receiving Leukeran. Partners should be informed of the drugs affect on germ cells. This product should not be used in pregnancy, particularly in the first trimester, unless considered absolutely essential by the physician.</p><p><u>Breast-feeding</u><br />Mothers receiving Leukeran should not breast-feed.</p><p><u>Fertility</u><br />Chlorambucil may cause suppression of ovarian function and amenorrhoea has been reported following chlorambucil therapy.<br />Azoospermia has been observed as a result of therapy with chlorambucil although it is estimated that a total dose of least 400 mg is necessary. Varying degrees of recovery of spermatogenesis have been reported in patients with lymphoma following treatment with chlorambucil in total doses of<br />410-2600 mg.</p><p><u>Teratogenicity</u><br />As with other cytotoxic agents Leukeran is potentially teratogenic (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No information on the effects of Chlorambucil on the ability to drive and use machines is available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For this product there is no modern clinical documentation which can be used as support for determining the frequency of undesirable effects. Undesirable effects may vary in their incidence depending on the dose received and also when given in combination with other therapeutic agents.</p><p>&nbsp;</p><p>The following convention has been utilised for the classification of frequency: Very common (&ge;1/10), common (&ge;1/100 and &lt;1/10), uncommon (&ge;1/1000 and &lt;1/100), rare (&ge;1/10,000 and &lt;1/1000) and very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Body System</p></td><td style="vertical-align:top"><p>Side effects</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified</p><p>(including cysts and polyps)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Acute secondary haematologic malignancies (especially leukaemia and myelodysplastic syndrome), particularly after long term treatment.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Leukopenia, neutropenia, thrombocytopenia, pancytopenia or bone marrow suppression<sup>1</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anaemia.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Irreversible bone marrow failure.</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypersensitivity such as urticaria and angioneurotic oedema following initial or subsequent dosing.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Convulsions in the paediatric population with nephrotic syndrome.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Convulsions <sup>2</sup>, partial and/or generalised in the paediatric</p><p>population and adults receiving therapeutic daily doses or high pulse dosing regimens of chlorambucil.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Movement disorders including tremor, muscle twitching</p><p>and myoclonus in the absence of convulsions. Peripheral neuropathy.</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Interstitial pulmonary fibrosis<sup>3</sup>, interstitial pneumonia.</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Gastro-intestinal disorders such as nausea and vomiting, diarrhoea and mouth ulceration.</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hepatoxicity, jaundice.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome, toxic epidermal necrolysis<sup>4</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Sterile cystitis.</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Amenorrhoea, azoospermia.</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and</p><p>administration site conditions</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pyrexia.</p></td></tr></tbody></table><p>1. Although bone marrow suppression frequently occurs, it is usually reversible if chlorambucil is withdrawn early enough.<br />2. Patients with a history of seizure disorder may be particularly susceptible.<br />3. Severe interstitial pulmonary fibrosis has occasionally been reported in patients with chronic lymphocytic leukaemia on long term chlorambucil therapy. Pulmonary fibrosis may be reversible on withdrawal of chlorambucil.<br />4. Skin rash has been reported to progress to serious conditions including Stevens-Johnson syndrome and toxic epidermal necrolysis.</p><p><u>To report any side effect(s):</u></p><p><strong>&nbsp;Saudi Arabia:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>&bull;&nbsp;&nbsp; &nbsp;The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp; &nbsp;SFDA Call Center: 19999<br />-&nbsp;&nbsp; &nbsp;E-mail: npc.drug@sfda.gov.sa<br />-&nbsp;&nbsp; &nbsp;Website: https://ade.sfda.gov.sa/ &nbsp;</p></td></tr></tbody></table><p><strong>- Other GCC States:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>Please contact the relevant competent authority.</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and signs</u><br />Reversible pancytopenia was the main finding of inadvertent overdoses of chlorambucil. Neurological toxicity ranging from agitated behaviour and ataxia to multiple grand mal seizures has also occurred.</p><p><u>Treatment</u><br />As there is no known antidote the blood picture should be closely monitored and general supportive measures should be instituted, together with appropriate blood transfusion if necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic Group: Antineoplastic and immunomodulating agents, antineoplastic agents, alkylating agents, nitrogen mustard analogues, ATC Code: L01AA02.</p><p><u>Mechanism of action</u><br />Chlorambucil is an aromatic nitrogen mustard derivative which acts as a bifunctional alkylating agent. In addition to interference with DNA replication, chlorambucil induces cellular apoptosis via the accumulation of cytosolic p53 and subsequent activation of an apoptosis promoter (Bax).</p><p><u>Pharmacodynamic effects</u><br />The cytotoxic effect of chlorambucil is due to both chlorambucil and its major metabolite, phenylacetic acid mustard (see section 5.2).</p><p><u>Mechanism of resistance</u><br />Chlorambucil is an aromatic nitrogen mustard derivative and resistance to nitrogen mustards has been reported to be secondary to: alterations in the transport of these agents and their metabolites via various multi-resistant proteins, alterations in the kinetics of the DNA cross-links formed by these agents and changes in apoptosis and altered DNA repair activity. Chlorambucil is not a substrate of multi-resistant protein 1 (MRP1 or ABCC1), but its glutathione conjugates are substrates of MRP1 (ABCC1) and MRP2 (ABCC2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u><br />Chlorambucil is well absorbed by passive diffusion from the gastrointestinal tract and is measurable within 15-30 minutes of administration. The bioavailability of oral chlorambucil is approximately 70% to 100% following administration of single doses of 10-200 mg. In a study of 12 patients administered approximately 0.2 mg/kg of oral chlorambucil, the mean dose adjusted maximum plasma concentration (492 &plusmn; 160 nanograms/ml) occurred between 0.25 and 2 hours after administration.</p><p>Consistent with the rapid, predictable absorption of chlorambucil, the inter-individual variability in the plasma pharmacokinetics of chlorambucil has been shown to be relatively small following oral dosages of between 15 and 70 mg (2-fold intra-patient variability, and a 2-4 fold interpatient variability in AUC).</p><p>The absorption of chlorambucil is reduced when taken after food. In a study of ten patients, food intake increased the median time to reach Cmax by greater than 100%, reduced the peak plasma concentration by greater than 50% and reduced mean AUC (0-ꝏ) by approximately 27% (see section 4.2).</p><p><u>Distribution</u><br />Chlorambucil has a volume of distribution of approximately 0.14-0.24 L/kg. Chlorambucil covalently binds to plasma proteins, primarily to albumin (98%), and covalently binds to red blood cells.</p><p><u>Biotransformation</u><br />Chlorambucil is extensively metabolised in the liver by monodichloroethylation and &beta;-oxidation, forming phenylacetic acid mustard (PAAM) as the major metabolite, which possesses alkylating activity in animals. Chlorambucil and PAAM degrade in vivo forming monohydroxy and dihydroxy derivatives. In addition, chlorambucil reacts with glutathione to form mono- and diglutathionyl conjugates of chlorambucil.</p><p>Following the administration of approximately 0.2 mg/kg of oral chlorambucil, PAAM was detected in the plasma of some patients as early as 15 minutes and mean dose adjusted plasma concentration (Cmax) of 306 &plusmn; 73 nanograms/ml occurred within 1 to 3 hours.</p><p><u>Elimination</u><br />The terminal phase elimination half-life ranges from 1.3-1.5 hours for chlorambucil and is approximately 1.8 hours for PAAM. The extent of renal excretion of unchanged chlorambucil or PAAM is very low; less than 1% of the administered dose of each of these is excreted in the urine in 24 hours, with the rest of the dose eliminated mainly as monohydroxy and dihydroxy derivatives.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mutagenicity and Carcinogenicity</u><br />As with other cytotoxic agents chlorambucil is mutagenic in in vitro and in vivo genotoxicity tests and carcinogenic in animals and humans.</p><p><u>Effects on fertility</u><br />In rats, chlorambucil has been shown to damage spermatogenesis and cause testicular atrophy.</p><p><u>Teratogenicity</u><br />Chlorambucil has been shown to induce developmental abnormalities, such as short or kinky tail, microcephaly and exencephaly, digital abnormalities including ectro-, brachy-, syn- and polydactyly and long-bone abnormalities such as reduction in length, absence of one or more components, total absence of ossification sites in the embryo of mice and rats following a single oral administration of 4-20 mg/kg. Chlorambucil has also been shown to induce renal abnormalities in the offspring of rats following a single intraperitoneal injection of 3-6 mg/kg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Core</u><br />Microcrystalline cellulose<br />Lactose, anhydrous<br />Colloidal anhydrous silica<br />Stearic acid</p><p><u>Coat</u><br />Hypromellose<br />Titanium dioxide<br />Macrogol/ PEG 400<br />Synthetic red and yellow iron oxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator between 2C - 8C. Store in the original container.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Leukeran tablets are supplied in amber (Type III) glass bottles with a child resistant polypropylene/ HDPE closure containing 25 and 50 tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Safe handling of Leukeran tablets:-The handling of Leukeran Tablets should follow guidelines for the handling of cytotoxic drugs according to prevailing local recommendations and/or regulations (for example, Royal Pharmaceutical Society of Great Britain Working Party on the Handling of Cytotoxic Drugs).</p><p>Provided the outer coating of the tablet is intact, there is no risk handling Leukeran Tablets. Pregnant staff should not handle cytotoxic agents. Leukeran Tablets should not be divided.</p><p><u>Handling:</u></p><ul><li>Leukeran is a cytotoxic drug. Considered a carcinogenic in humans.</li><li>&nbsp;In healthcare settings, use designated area for medication storage and restrict access to only authorized personal.</li><li>To minimize the risk of dermal exposure, always wear chemotherapy gloves and sleeve covers when handling Leukeran. This includes all handling activities in clinical settings, pharmacies, storerooms and home healthcare settings, including receiving, unpacking and, and storing within a facility.</li><li>&nbsp;For transportation of intact tablet within the facility, wear single chemotherapy gloves and place in double bag or in a sealed container.</li><li>The tablets should not be divided, broken or crushed. This might produce powder that can contaminate workplace surfaces.</li><li>&nbsp;Caution should be observed in handling broken or crushed tablets; wear double chemotherapy gloves and place in double bag or in a sealed container. Avoid direct contact with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with sterile water, or plain water if sterile water is unavailable.</li><li>When manipulations are necessary such as compounding, crushing, cutting, or splitting; should be performed within a ventilated engineering enclosure and/ or augment the control of generated aerosols using supplementary controls such as glove bags or pill pouches that contain the hazardous drug during and after the crushing process.</li><li>Wear double chemotherapy gloves, protective gown and sleeve covers. Add eye/face protection and respiratory protection [N95] if compounding is done outside of the ventilated engineering control. Hair and shoe covers should be worn.</li><li>&nbsp;When clinically appropriate, add liquid or moist products to crushed hazardous drug product as soon as possible after crushing, to avoid the potential of subsequent aerosol dissemination.</li><li>&nbsp;For medication administration, wear single chemotherapy gloves with intact and coated tablets and double chemotherapy gloves with cut or crushed tablets. Add eye and face protection if there is the potential to contact vomit or if patient may resist or is pre-disposed to spitting out.</li><li>&nbsp;Personnel who are pregnant should avoid exposure to crushed or broken coated tablets.</li></ul><p><u>Disposal: </u></p><ul><li>Wear double chemotherapy gloves and protective gown for any disposal or cleaning activity of medication contaminated waste.</li><li>&nbsp;Avoid creating dusts. Place in sealed bags for disposal. Use caution when closing bags as pushing waste down may force hazardous drug dusts up into the user&rsquo;s face.</li><li>For disposal of drugs and metabolites in body fluids, wear chemotherapy gloves and protective gown. Fold soft materials (sheets, hygiene care products) inward to prevent leakage and place in sealed bags.</li><li>In case of spill, limit access to area, use wet wiping method (absorbent pads for liquid spills). Place in sealed bags for disposal. Disinfection, deactivation or decontamination agents may be necessary.</li><li>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen Pharma Trading Limited
 3016 Lake Drive,
Citywest Business Campus,
 Dublin 24, Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>